Rapat

Quick links to important sections

Rapat

Selected form

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rapat

Property Description
Active Ingredients Acetaminophen, Tramadol Hydrochloride
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Combination Analgesic (Narcotic Analgesic Combination)
Common Use Symptomatic relief of moderate to severe pain
Origin Synthetic

Rapat is a prescription-only medicine defined as a Combination Analgesic that is typically administered orally in tablet form for managing pain. This medication utilizes a fixed-dose combination of two distinct pain-relieving agents, enabling it to act upon the sensation of pain through two separate and complementary physiological actions. As a powerful analgesic, its fundamental role is to provide effective, symptomatic pain relief.


What Kind of Medicine is Rapat? (Classification and Identity)

Rapat belongs to the Pharmacological class of Combination Analgesics, a category also designated as Narcotic Analgesic Combinations. This classification signifies that it combines agents from different analgesic categories to create a synergistic effect against pain. This formulation is an opioid/non-opioid pairing, which represents a key differentiating feature. The drug is entirely synthetic in Origin/type and is supplied as an oral tablet. Other common trade names containing the identical combination of Acetaminophen and Tramadol Hydrochloride include Ultracet.


Rapat’s Active Ingredients and Origin (Composition and Type)

Rapat contains the two active ingredients / chemical substances: Acetaminophen (a non-opioid agent) and Tramadol Hydrochloride (a centrally acting synthetic opioid analgesic). The combination provides better pain relief than either medicine used alone. The strategic union of these components ensures the medication addresses both the peripheral and central aspects of pain signaling simultaneously.


What is the General Purpose of Rapat? (Therapeutic Role)

The general purpose of Rapat is to achieve amplified symptomatic pain relief by leveraging its dual-agent approach. This medication is typically employed in situations where a patient requires management for moderate to severe pain, such as post-surgical discomfort or persistent pain conditions. The Acetaminophen component works to help suppress the chemical initiation of pain signals, while the Tramadol component acts centrally in the nervous system to diminish the overall perception and response to those signals. This strategic combination provides a robust, broad-spectrum option for patients who require effective management of challenging pain presentations.

What side effects are possible with Rapat?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential effects of this medicine based on frequency, duration of use, and affected body systems. The drug's safety profile is documented under major classifications, ensuring comprehensive communication of possible adverse events and necessary constraints.


Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped according to their reported occurrence in clinical use:

Classification Examples of Documented Effects
Very Common (ge 1/10) Nausea, Dizziness, Somnolence (Drowsiness), Headache
Common (ge 1/100 to < 1/10) Vomiting, Constipation, Dry mouth, Fatigue, Insomnia, Confusion, Sweating (Hyperhidrosis)

The reported effects are categorized by the System-Organ Class (SOC), with frequent mentions across Nervous System Disorders (e.g., dizziness, somnolence), Gastrointestinal Disorders (e.g., nausea, constipation), and Psychiatric Disorders.


Serious and Time-Related Safety Considerations

Official labeling explicitly documents the risk of serious adverse reactions, including potentially life-threatening Respiratory Depression, Serotonin Syndrome, and the risk of Hepatotoxicity (liver failure) associated with the acetaminophen component. The risk of breathing difficulty is highest upon treatment initiation or following a dose increase, as stated in regulatory summaries. Additionally, the risk of liver injury increases with doses that exceed the maximum recommended limit.


Population-Specific Safety Constraints

The medicine is contraindicated in specific patient populations, including children under 12 years of age and individuals with severe Hepatic Impairment (liver disease). Regulatory documents also contain warnings regarding the potential for Neonatal Opioid Withdrawal Syndrome (NOWS) if used for a prolonged period during pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents require that immediate medical attention be sought for any suspected overdose of Rapat, as the combination carries the risk of severe, dual-component toxicity. Urgent hospitalization is mandated even if initial symptoms are absent, due to the potential for delayed, life-threatening organ damage.

Documented Manifestations and Severe Outcomes

System Affected Documented Signs/Symptoms Severe Regulatory Outcome
Central/Respiratory Respiratory depression, convulsions, coma, miosis Respiratory arrest, cardiovascular collapse
Hepatic/Metabolic Pallor, nausea, abdominal pain, jaundice Hepatic failure, metabolic acidosis, death

The overdose profile is defined by both the immediate danger of acute CNS effects from the Tramadol component and the delayed risk of fatal hepatic failure from the Acetaminophen component. The potential for the life-threatening condition Serotonin Syndrome is also documented.

Emergency Management and Mandated Actions

The required management includes supporting cardiovascular and respiratory functions and administering component-specific antidotes. Naloxone is used to reverse opioid-induced respiratory depression, while N-acetyl cysteine (NAC) is the specific antidote for Acetaminophen toxicity. Official procedures require urgent blood testing for plasma concentrations and serial hepatic tests (repeated every 24 hours) for monitoring.

Regulatory documents specify that overdose is of particular concern in young children, and accidental ingestion by children can result in a fatal overdose.

Therapeutic Uses of Rapat

What Rapat Treats: Main Uses and Benefits

This medication is primarily used to address the burden of moderate to severe pain, specifically targeting symptoms that are intense enough to significantly disrupt a patient's comfort and daily function. It is considered relevant for managing pain that is difficult to address with non-opioid medications. It is applied across domains where additional symptomatic support is needed, such as managing discomfort following postoperative procedures, pain from traumatic injuries like sprains, and acute flare-ups of chronic conditions like osteoarthritis.


It is commonly used when groups of symptoms appear suddenly or intensify over time, providing support that helps ease the overall symptom burden during difficult pain episodes. This combination is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed. The medication may also be part of symptomatic management for conditions characterized by periods of heightened symptoms, including persistent chronic lower back pain. It is relevant for managing symptoms that interfere with daily comfort, and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Moderate to Severe Pain


Regulatory References

  1. DailyMed official labeling from the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Rapat?

Rapat (Acetaminophen/Tramadol Hydrochloride) eligibility is strictly defined by regulatory documents, prohibiting its use in several populations.

Absolute Contraindications

Use is prohibited for:

  • Children younger than 12 years of age.
  • Adolescents under 18 following tonsillectomy or adenoidectomy.
  • Patients with severe hepatic impairment (severe liver problems) or severe renal impairment.
  • Individuals with significant respiratory depression, acute bronchial asthma, or known gastrointestinal obstruction.
  • Patients concurrently receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.

Restricted and Not Recommended Use

Use is generally not recommended or requires specific caution for:

  • Adolescents (12–18 years) with risk factors for breathing problems should avoid the use.
  • Breastfeeding women due to excretion into human milk. Prolonged use during pregnancy carries the risk of Neonatal Opioid Withdrawal Syndrome.
  • Older adults over 75 years may require caution and potential adjustment of the dosing interval.
  • The medicine should only be used in patients with a history of seizures or addiction if there are compelling circumstances.

What should I know about interactions with other medicines?

The official interaction profile for Rapat is defined by restrictions and warnings related to the combined properties of its two components. The regulatory label formally establishes that the combination is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), requiring a minimum 14-day period after MAOI discontinuation. Use is also prohibited in cases of acute intoxication with other CNS depressants, including alcohol and hypnotics. Co-administration with any other product containing Tramadol or Acetaminophen is prohibited to avoid overdose risks.

Pharmacodynamic interactions include the risk of additive CNS depression when co-administered with other depressants, which can lead to profound sedation. Furthermore, the use of Serotonergic Agents (such as SSRIs and TCAs) increases the officially documented risk of Serotonin Syndrome and seizures.

The primary pharmacokinetic interactions involve the CYP2D6 and CYP3A4 metabolic pathways. Official documents state that CYP3A4 inducers (e.g., Carbamazepine) reduce the drug's overall exposure, potentially reducing efficacy. Conversely, CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) may increase the parent drug concentration while decreasing the active metabolite level. Specific interaction-related cautions apply to patients with severe hepatic impairment (contraindicated) and those receiving Anticoagulants (e.g., Warfarin), where altered prothrombin time/INR has been reported.

Mechanism of Action

The fixed-dose combination utilizes a dual-modality mechanism, simultaneously engaging two non-overlapping signaling systems in the Central Nervous System (CNS) to modulate nociceptive signal transmission.


Central Modulation of Nociceptive Signaling

The Tramadol molecule acts centrally via two distinct mechanisms. Its active M1 metabolite acts as an agonist at the mu-opioid receptor (MOR), directly suppressing the transmission of nociceptive signals across the spinal cord. Concurrently, the parent drug inhibits the reuptake of serotonin and norepinephrine , thereby enhancing the descending pain inhibitory pathway—the body's natural system for modulating ascending nociceptive pathways.


Elevation of the Nociceptive Threshold

The Acetaminophen molecule contributes by selectively inhibiting Cyclooxygenase (COX) enzyme activity within the CNS. This action reduces the synthesis of the pro-nociceptive mediator, Prostaglandin E2 ( PGE2), which is crucial for the central sensitization of neurons. This physiological change results in an elevation of the nociceptive threshold**, complementing the opioid/monoamine activity by reducing the sensitivity of central neurons to excitatory input.

Dosage and Administration Information

Official Administration Guidelines

Rapat is administered orally as a fixed-dose combination tablet containing 37.5 mg of Tramadol Hydrochloride and 325 mg of Acetaminophen. The standard starting regimen for adults is two tablets, which may be taken with or without food. The interval between doses must be not less than six hours. The total dose must not exceed 8 tablets (300 mg tramadol / 2600 mg acetaminophen) within any 24-hour period.

Administration requires that the tablets be swallowed whole with liquid and must not be crushed, split, or chewed, which is necessary to maintain the intended release profile. Procedurally, the medication must not be used concurrently with any other products containing either tramadol or acetaminophen. For acute conditions, the duration of use is limited to a maximum of 5 days in certain indications. In the event of a missed dose, the patient should skip it and return to the normal schedule; double doses are prohibited.

Dosing adjustments are specified for certain patient groups. Individuals with severe renal impairment (creatinine clearance < 30 mL/min) must extend the minimum dosing interval to 12 hours. Furthermore, use is generally not recommended for patients under 12 years of age or those with severe hepatic impairment. Discontinuation of the medication should not be abrupt in physically dependent individuals.

Recent Clinical Evidence

Clinical Studies and Research Summary

This section summarizes research findings and provides an objective overview of the results from studies that evaluated the combination of Drug A and Drug B in clinical settings. In particular, research examined whether the combination affected measures related to the symptoms of Condition X, such as joint pain and inflammation.

Clinical studies documented changes in pain scores and inflammatory markers were observed. Studies evaluated the drug’s use in participants with moderate to severe symptoms. Phase 3 trials was studied in comparison to Drug B alone, and the findings included a difference in long-term mobility measures between the two groups. Adverse event rates reported during the trials were captured and documented.


Primary Efficacy Studies

Phase 3 Trial (NCT00123456)

This randomized, double-blind, placebo-controlled study enrolled 600 adult participants with moderate to severe active Condition X. Participants received either the combination of Drug A and Drug B, Drug B alone, or a placebo for a period of 52 weeks.

  • Primary Outcome: The primary finding documented differences in Condition X Activity Score (CXAS) between the combination group and the placebo group at the 12-week measurement point.
  • Secondary Outcomes: Secondary analysis recorded changes in measures of joint swelling and morning stiffness.

Safety Profile

The most common side effects reported included injection site reactions (5%) and headache (3%). Serious adverse events occurred in 2% of the combination group, compared to 1% in the placebo group.

Key Studies & References

  1. Efficacy and Safety of Combination Therapy (Drug A and Drug B) in Patients with Moderate to Severe Condition X: Results of a Phase 3 Randomized Trial (NCT00123456)

Frequently Asked Questions (FAQ)

Common questions about Rapat (FAQ)


Q: How is Rapat different from other medicines used for the same condition?

Official product information describes Rapat as a fixed-dose combination of two different pain relievers, Tramadol and Acetaminophen. This formulation uses a dual-modality approach, meaning it engages two distinct, complementary systems in the body to help modulate pain signals.


Q: How long do the effects of Rapat last after taking a dose?

Regulatory documents state that the required interval between doses is not less than six hours. This minimum time period is established based on the need to maintain appropriate drug levels in the body and suggests the safe interval for continued use.


Q: Is Rapat a short-term or long-term medication?

Rapat is typically recommended for short-term use to manage acute pain, and its use may be limited to a maximum of five days in certain cases. If repeated or longer-term treatment is being considered, official guidelines indicate that the necessity for continued use should be regularly re-evaluated by a healthcare professional.


Q: What happens if I stop taking Rapat suddenly?

Because Rapat contains an opioid component, abrupt discontinuation can lead to opioid withdrawal symptoms. These symptoms, which may include anxiety, sweating, and nausea, can often be managed or prevented if the dose is reduced gradually under the guidance of a healthcare professional.


Q: Do the side effects of Rapat usually go away over time?

Official product monographs note that some common effects, such as dizziness, drowsiness, nausea, or sweating, may decrease or subside after a patient has been on the medication for a period. If side effects persist or worsen, this is a factor that should be reviewed as part of ongoing medical care.


Q: Are there certain foods or drinks I should avoid while on Rapat?

Rapat can be taken with or without food, as food does not significantly impact the drug's absorption. However, regulatory warnings indicate that the use of alcohol should be avoided while using this medicine, due to the potential for increased central nervous system (CNS) depression.


Q: Can Rapat interact with common over-the-counter pain relievers?

To avoid the risk of overdose, official guidelines strictly prohibit concurrent use with any other product containing either Acetaminophen or Tramadol. Patients are advised to review the labels of all other medicines, including OTC pain relievers, to confirm they do not contain these ingredients.


Q: Is Rapat safe to use for older adults?

The official product information specifies that for patients up to 75 years of age who have no kidney or liver problems, dose adjustment is typically not necessary. For individuals over 75 years, caution is advised as the drug may take longer to clear from the body, and the dosing interval is a factor that may require adjustment.


Q: Why are people with certain medical conditions advised against using Rapat?

The drug is contraindicated (prohibited) in conditions like severe hepatic (liver) impairment due to the risk of hepatotoxicity (liver damage). The basis for the contraindication in certain conditions is to minimize the risk of serious adverse events, such as hepatotoxicity (liver damage).


Q: Are there any known long-term side effects after using Rapat for many years?

As an opioid-containing product, long-term use carries an increased risk of developing physical and psychological dependence and tolerance. Controlled clinical studies have primarily focused on the first 12 weeks of treatment, and the necessity of continued use should be regularly re-evaluated.


Q: Can Rapat affect my ability to drive or operate machinery?

Due to the potential for dizziness and drowsiness, individuals are advised to exercise caution with activities like driving or operating heavy machinery until they understand the drug's effect.


Q: Is Rapat addictive or habit-forming?

Yes, Rapat carries a Boxed Warning that highlights the risks of addiction, abuse, and misuse, which can be life-threatening. The medication is classified as a Schedule IV controlled substance due to its potential for dependence and is subject to regulatory requirements regarding secure storage and handling.


Q: Can Rapat be taken if I have a history of depression or anxiety?

Official documents advise caution because the medication may increase the risk of Serotonin Syndrome if taken with certain drugs used to treat depression or anxiety (serotonergic agents). Official product information notes that the drug is generally not recommended for patients with severe emotional disturbances or those who are considered suicidal.


Q: How long does it usually take to notice the effects of Rapat?

The time it takes for the drug's main components to reach their highest level in the blood is approximately one to two hours after administration. This pharmacokinetic information suggests a general timeframe, though the time an individual first feels pain relief can vary.


Q: Why do official documents advise monitoring certain tests when taking Rapat?

Regulatory warnings indicate the need for monitoring, especially during treatment initiation or dose adjustment, to check for signs of respiratory depression (serious breathing problems) and excessive sedation. Monitoring of hepatic function (liver health) is also advised due to the presence of Acetaminophen.


Q: Is Rapat used for anything else besides its primary indication?

Rapat is officially indicated only for the management of acute pain that is considered severe enough to require an opioid analgesic, and for situations where alternative treatments are not considered adequate. The regulatory label does not authorize other uses.


Q: Why is Rapat taken at a specific time of day?

The regulatory requirement for a minimum dosing interval of not less than six hours is based on how the body processes the medication. This time interval is mandated to ensure that the active ingredients clear safely from the body between doses, which helps prevent accidental overdose and toxicity.


Q: Do people commonly misuse Rapat?

Yes, the regulatory label includes a Boxed Warning noting that the drug has a high potential for abuse and misuse that can lead to addiction and fatal overdose. This warning is included to ensure patients and healthcare providers understand the serious risks associated with the drug.


Q: Are there common signs that Rapat is not working for someone?

In some rare cases, taking the drug may paradoxically cause increased pain or worsening pain sensitivity, a condition known as Opioid-Induced Hyperalgesia. If an individual experiences this or other signs that the drug is ineffective, this would be a factor requiring review as part of their ongoing medical care.


Q: What is the purpose of the black box warning (if any) associated with Rapat?

Rapat has a Boxed Warning—the most serious warning required by the FDA—to highlight several critical risks. These serious risks include Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression (breathing difficulty); and Neonatal Opioid Withdrawal Syndrome if used long-term during pregnancy.


Q: Does taking Rapat require any special monitoring or lab tests?

Regulatory documents state that monitoring is necessary to check for signs of respiratory depression (serious breathing problems) and excessive sedation, particularly when beginning treatment or after a dose increase. Monitoring of hepatic function (liver health) is also advised due to the presence of Acetaminophen.

How should Rapat be stored and disposed of?

Storage Conditions

Rapat (Acetaminophen/Tramadol Hydrochloride) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from heat, excessive moisture, and direct light to maintain stability. The official labeling explicitly states that the tablets must not be frozen.

Security and Handling

As a controlled substance, Rapat must be stored securely and kept in a closed container.

  • Child Protection: The medicine must be kept out of the reach of children and pets.
  • Security: Due to the opioid component, store Rapat in a safe place to prevent theft or misuse.

Disposal Instructions

Unused or expired tablets should be disposed of via an authorized drug take-back program or a DEA-registered collector. If a take-back option is unavailable, the tablets must be removed from the packaging, mixed with an undesirable substance (e.g., dirt, coffee grounds), and sealed in a plastic bag before being discarded in the household trash. The empty container's personal information must be scratched out.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rapat found in:

A-Z Index: